Liraglutide Offers Long-Term Stability and Expands Hydreight’s Comprehensive GLP-1 Weight Management Portfolio

Hydreight Technologies Inc., a fast-growing mobile clinical network and medical platform which enables flexible at-home medical services across 50 states in the United States, is pleased to announce the expansion of its VSDHOne platform with the launch of Liraglutide. This addition marks a strategic expansion of Hydreight’s growing GLP-1 weight management and wellness offerings, strengthening its commitment to accessible and innovative solutions through its national telehealth network.

Hydreight’s current GLP-1 offerings now include:

  • Semaglutide (weekly injectable)
  • Tirzepatide (dual-action, weekly injectable)
  • Liraglutide (newly launched, daily injectable)
  • Sublingual & Buccal GLP-1s (needle-free administration)

These offerings include a range of delivery methods to meet the diverse needs of patients and providers—from weekly or daily injectables to sublingual and buccal formats. Sublingual doses are dissolved under the tongue, and buccal is absorbed through the cheek, offering flexibility for those who prefer not to use needles while maintaining consistent dosage options. This variety ensures tailored, scalable solutions for weight management and metabolic care.

A Strategic Addition for Stability & Choice

As demand for GLP-1 medications surges, Hydreight’s inclusion of Liraglutide introduces a stable, patent-free, and clinically proven option—ideal for patients and providers seeking consistent long-term therapies amid evolving supply and regulatory landscapes. Unlike newer GLP-1 entrants, Liraglutide’s established track record and daily dosing format offer flexibility without compromising efficacy.

“The launch of Liraglutide further deepens our commitment to expanding access to proven GLP-1 therapies,” said Shane Madden, CEO of Hydreight. “It doesn’t replace anything—it expands our offering. No matter how the landscape shifts, Hydreight users can count on a complete and reliable GLP-1 portfolio.”

Why Liraglutide?

Liraglutide is a GLP-1 receptor agonist used in the management of obesity and type 2 diabetes. Delivered via once-daily injection, it offers consistent and clinically proven efficacy. Compared to sublingual GLP-1s, which have lower bioavailability and shorter duration of action, Liraglutide’s injectable form ensures direct systemic absorption and predictable, long-lasting effects.

Health Technology Insights: Texas Star Pharmacy Expands Pharmetric Lab Partnership

Comprehensive & Customizable Delivery Options Hydreight’s GLP-1 portfolio now supports multiple delivery methods:

  • Injectables: Weekly, biweekly, or daily based on patient needs
  • Sublingual: Dissolved under the tongue
  • Buccal: Absorbed through the inner cheek

This mix of injectable, sublingual, and buccal options positions Hydreight as a category leader in GLP-1 administration versatility. It allows medical professionals to provide customized, scalable care while ensuring patient adherence and comfort.

Health Technology Insights: Spectrum Vascular Welcomes New Executive Leadership

Unlocking Access via VSDHOne

The VSDHOne platform enables a seamless patient journey—from telehealth consultation to prescription and nationwide delivery. It supports medical professionals with flexible tools while ensuring regulatory compliance across all services.

“Hydreight isn’t just a tech stack—we’re a full-service medical infrastructure,” added Madden. “With over 400 licenses sold across the U.S., we’re creating a scalable, future-ready solution for wellness, weight loss, and personalized healthcare.”

The addition of Liraglutide and sublingual/buccal routes of administration for the GLP1s reflects Hydreight’s mission to expand access to premium wellness and weight management therapies through a convenient, compliant, and nationwide telehealth network. The VSDHOne platform simplifies the entire patient journey from telehealth consult to prescription and delivery, while offering medical professionals the flexibility to provide treatments at scale.

Health Technology Insights: Children’s Hospital Uses UKG Workforce Intelligence for Growth

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source – GlobalNewswire